Re-purposing clinical drugs as anti-infective therapies against HCV


In another large collaboration between multiple groups in Germany and Alberta, the HAI-IDR has identified the anti-HCV activities of a family of clinically used drugs, flunarizine and the related calcium channel blockers. These studies open the possibility of immediately testing the potential of clinical drugs of low cost against HCV.


Research Partners: